The partnership is broad and includes business, the regions, academia, patient organizations and authorities.

“The partnership will make Sweden an even more attractive country for research and development collaborations. It creates the conditions for more patients to have access to treatments at the absolute forefront,” says Ann Lindberg, Director General of the Swedish Medical Products Agency.

A functioning partnership between healthcare and industry

A council with representation from the partnership’s stakeholders will be linked to the initiative and will have a central role in ensuring that SweTrial works in line with the goals and priorities that are jointly developed. The council’s influence over how SweTrial is developed and delivered will thus be significant and contribute to transparency and efficiency characterized by participation and shared responsibility.

“A functioning partnership between healthcare and industry will be key to increasing the pace of clinical studies. Our preliminary study has created a broad consensus between the parties and now we are all ready to act,” comments Jessica Martinsson, CEO of SwedenBIO.

An office at the Medical Products Agency

The decision also means that an office for SweTrial will be established at the Medical Products Agency.

“We are very much looking forward to getting started on establishing the office. The Medical Products Agency has extensive experience in both collaboration and clinical trials, and regulatory expertise that will be a very valuable contribution to SweTrial,” says Ann Lindberg.